Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (Nordic Exchange: BINV) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.

Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of receipt of such clearance), Roche will pay ThromboGenics and BioInvent an upfront payment of EUR50 million. In addition, ThromboGenics and BioInvent could potentially receive up to EUR450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. ThromboGenics and BioInvent will retain co-promotion rights for the product in the Benelux, Baltic and Nordic regions.

ThromboGenics and BioInvent are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers. Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by ThromboGenics and BioInvent. ThromboGenics and BioInvent in conjunction with Roche will form a Joint Steering Committee to oversee research and development activities. In addition, Roche will also provide funding to ThromboGenics and BioInvent for research on non-cancer indications an
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... 21, 2014 Telomere Biosciences, LLC (Telomere ... "TELO-20 for Dogs" with Telomerase Activation Complex ... the world for dogs. Telomeres are the protective ... the body. A wealth of ground-breaking research by ... Science and Aging, including Nobel laureates, has demonstrated ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... April 23 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ... an agreement,with Abbott Laboratories pursuant to which it ... promissory note with Abbott issued in,connection with its ... to,the urokinase assets, including the remaining inventory of ...
... PHILADELPHIA, April 23 BioNanomatrix, Inc. today,announced that ... honored at the,14th Annual Ben Franklin Emerging Business ... Management Team category, competing with a,strong group of ... executive officer Dr. Michael Boyce-Jacino accepted the,award on ...
... Calif., April 23 SectorWatch.biz announces the,availability ... news and driving,markets today within the biotechnology ... on the aforementioned equities and the,opportunity for ... on the,subject and sector., Investors can ...
Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan ... has agreed to a partnership with Gabriel Health ... fastest growing Certified Nursing Assistant preparatory ... Institute  an exclusive member of Binary,s LiveScan service ... Biometrics will improve its service capabilities by ...
(Date:8/21/2014)... at improving the food intake, health and quality of ... among three projects at the University of Waterloo receiving ... Institutes of Health Research (CIHR). , Professor Heather ... Waterloo, and a Schlegel research chair in nutrition and ... why many Canadians living in long-term care homes are ...
(Date:8/21/2014)... BOSTON -- Nine researchers from Beth Israel ... included in "The World,s Most Influential Scientific Minds ... from Thomson Reuters ScienceWatch, a web resource for science ... scientists recognized as among the most influential "are performing ... to the advancement of their science," according to a ...
Breaking Biology News(10 mins):LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Grants will fund landmark aging research at Waterloo 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... United Nations Intergovernmental Panel on Climate Change (IPCC) have warned ... achieve a stable climate on our planet by the end ... coming decades must be curbed before the emissions can be ... CO2 emissions that can be tolerated globally by the end ...
... genetically modified crops, according to new research funded by ... A group at the Open University, led by Professor ... what large-scale, commodity farmers not those mainly involved ... know how consumers, governments and the food industry regard ...
... University of Nottingham could have a major impact on the ... to stay in work. Back pain is one of ... In 2004-5 approximately 34,000 people in the East Midlands suffered ... caused or made worse by their current or past work. ...
Cached Biology News:ETH Zurich competence center ESC introduces energy strategy 2ETH Zurich competence center ESC introduces energy strategy 3What farmers think about GM crops 2Helping back pain sufferers to stay in work 2
... kits are designed to rapidly and reliably ... patented APA Technology. APAgene provides hassle-free, ready-to ... All necessary ingredients are provided in each ... used for gap filling, localized cloning of ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
... product is designed to deparaffinize and perform ... fixed paraffin-embedded tissue sections mounted on glass ... the paraffin at the high temperature used ... emulsification of the paraffin by detergent. Formaldehyde ...
... product is designed to deparaffinize and perform ... fixed paraffin-embedded tissue sections mounted on glass ... the paraffin at the high temperature used ... emulsification of the paraffin by detergent. Formaldehyde ...
Biology Products: